[go: up one dir, main page]

WO2004041204A3 - Procedes et compositions pour le traitement de maladies neurodegeneratives - Google Patents

Procedes et compositions pour le traitement de maladies neurodegeneratives Download PDF

Info

Publication number
WO2004041204A3
WO2004041204A3 PCT/US2003/035106 US0335106W WO2004041204A3 WO 2004041204 A3 WO2004041204 A3 WO 2004041204A3 US 0335106 W US0335106 W US 0335106W WO 2004041204 A3 WO2004041204 A3 WO 2004041204A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
neurodegenerative diseases
treating neurodegenerative
ubiquitin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/035106
Other languages
English (en)
Other versions
WO2004041204A2 (fr
Inventor
Claudio A P Joazeiro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Priority to AU2003291730A priority Critical patent/AU2003291730A1/en
Publication of WO2004041204A2 publication Critical patent/WO2004041204A2/fr
Anticipated expiration legal-status Critical
Publication of WO2004041204A3 publication Critical patent/WO2004041204A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés et compositions permettant le traitement de maladies neurodégénératives par modulation de l'interaction entre l'ubiquitine et les motifs de liaison de l'ubiquitine.
PCT/US2003/035106 2002-11-04 2003-11-04 Procedes et compositions pour le traitement de maladies neurodegeneratives Ceased WO2004041204A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003291730A AU2003291730A1 (en) 2002-11-04 2003-11-04 Methods and compositions for treating neurodegenerative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42396102P 2002-11-04 2002-11-04
US60/423,961 2002-11-04

Publications (2)

Publication Number Publication Date
WO2004041204A2 WO2004041204A2 (fr) 2004-05-21
WO2004041204A3 true WO2004041204A3 (fr) 2006-05-11

Family

ID=32312728

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/035106 Ceased WO2004041204A2 (fr) 2002-11-04 2003-11-04 Procedes et compositions pour le traitement de maladies neurodegeneratives

Country Status (3)

Country Link
US (1) US20040171085A1 (fr)
AU (1) AU2003291730A1 (fr)
WO (1) WO2004041204A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8414774B2 (en) * 2001-04-25 2013-04-09 Agilent Technologies, Inc. Systems and methods for high-throughput screening of fluidic samples
US20050123970A1 (en) * 2001-04-25 2005-06-09 Can Ozbal High throughput autosampler
GB2443819B (en) * 2003-11-17 2009-09-02 Univ Auburn Methods and compositions for inhibiting intracellular aggregate formation
CN101454461A (zh) * 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
JP2011503548A (ja) * 2007-11-02 2011-01-27 バイオトローブ， インコーポレイテッド 質量分析装置をクロマトグラフィシステムに連結するための装置および方法
CA2825884A1 (fr) * 2011-01-31 2012-08-09 Oklahoma Medical Research Foundation Peptides a motifs interagissant avec l'ubiquitine utilises en tant que substances therapeutiques anticancereuses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726025A (en) * 1995-04-20 1998-03-10 President And Fellows Of Harvard College Assay and reagents for detecting inhibitors of ubiquitin-dependent degradation of cell cycle regulatory proteins
US20020004236A1 (en) * 2000-04-25 2002-01-10 Meyers Rachel A. 27960, a novel ubiquitin conjugating enzyme family member and uses therefor
WO2002011750A2 (fr) * 2000-08-08 2002-02-14 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Prevention de la neuro-toxicite de la proteine beta-amyloide par blocage de la voie proteolytique de l'ubiquitine-proteasome

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726025A (en) * 1995-04-20 1998-03-10 President And Fellows Of Harvard College Assay and reagents for detecting inhibitors of ubiquitin-dependent degradation of cell cycle regulatory proteins
US20020004236A1 (en) * 2000-04-25 2002-01-10 Meyers Rachel A. 27960, a novel ubiquitin conjugating enzyme family member and uses therefor
WO2002011750A2 (fr) * 2000-08-08 2002-02-14 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Prevention de la neuro-toxicite de la proteine beta-amyloide par blocage de la voie proteolytique de l'ubiquitine-proteasome

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] HERRING ET AL, Database accession no. 200100087932 *
SOCIETY FOR NEUROSCIENCE, vol. 26, no. 1-2, 2000 *

Also Published As

Publication number Publication date
AU2003291730A1 (en) 2004-06-07
AU2003291730A8 (en) 2004-06-07
US20040171085A1 (en) 2004-09-02
WO2004041204A2 (fr) 2004-05-21

Similar Documents

Publication Publication Date Title
WO2006071960A3 (fr) Compositions et procedes de traitement de troubles de la proliferation cellulaire
WO2006023651A3 (fr) Traitement prolonge de la sclerose en plaques
WO2006017295A3 (fr) Analogues de tetrapeptide
WO2006122156A3 (fr) Composes pour moduler la fonction trpv3
WO2007056124A3 (fr) Composés destinés à moduler la fonction de trpv3
AU2003253535A1 (en) N-4-piperidinyl compounds as ccr5 modulators
WO2003073999A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
WO2003074550A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
WO2001079164A3 (fr) Dithiocarbamates n-substitues utilises dans le traitement de troubles biologiques
WO2003082198A3 (fr) Procedes de traitement au moyen de modulateurs lxr
WO2004099388A3 (fr) Complexes de polypeptides cbl-b et methodes associees
AU2003223684A1 (en) Lxr modulators for the treatment of cardiovascular diseases
WO2005117939A3 (fr) Utilisation de ligands gpcr54 pour le traitement de l'infertilite
WO2003066097A3 (fr) Nouvelle cible pour inhiber l'angiogenese
WO2006053315A3 (fr) Methodes et compositions de traitement de maladies proliferatives cellulaires
AU2003903242A0 (en) Process for the treatment of wood
WO2004041204A3 (fr) Procedes et compositions pour le traitement de maladies neurodegeneratives
AU2002359459A1 (en) Treating b-cell mediated diseases by modulating dr6 activity
AU2003302822A1 (en) Antibodies to treat cancer
WO2004024077A3 (fr) Nouvelle composition et nouveaux procedes pour le traitement du psoriasis
AU2003259833A1 (en) Methods of treating neurodegenerative diseases
WO2003065997A3 (fr) Molecules anti-infarcissement
WO2004026892A3 (fr) Fragmentation d'adn
AU2003222667A1 (en) 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
WO2006091544A3 (fr) Procedes et compositions de modulation des canaux calciques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP